IP Library Granted Patent US 11,021,446
Granted Patent B2
US 11,021,446 · App. 16/854,762 · Granted Jun 1, 2021

Compositions and methods for modulating farnesoid X receptors

Inventors: Donatella Chianelli (San Diego, CA); Runyan Li (Shanghai, CN); Valentina Molteni (San Diego, CA); John Nelson (San Diego, CA); Jason Thomas Roland (San Diego, CA); Paul Vincent Rucker (Carlsbad, CA); David Charles Tully (Danville, CA); Xiaoyang Wang (Shanghai, CN); Liladhar Murlidhar Waykole (Succasunna, NJ); Yubo Zhang (Shanghai, CN); Bo Zhou (Emeryville, CA)
Assignee: Novartis AG
C07D231/54A61K31/416A61K31/4162A61K31/4439A61K31/4745C07D471/04C07D471/06C07D491/052
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,021,446
App. No.
16/854,762
Granted
Jun 1, 2021
Kind
B2
Abstract

The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Claims (13)

1. A method for preparing 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine monohydrate, comprising contacting 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid in a solvent with meglumine in water solution under suitable conditions, thereby providing 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine monohydrate.

2. The method of claim 1 , comprising adding said meglumine in water solution to a suspension of said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid in acetone.

3. The method of claim 1 , wherein said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine monohydrate has a dehydration point at about 71° C. by differential scanning calorimetry.

4. The method of claim 1 , further comprising heating said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine monohydrate at a temperature ranging from 60-90° C. under suitable conditions, thereby providing a 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt.

5. The method of claim 4 , comprising heating said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine monohydrate at about 80° C.

6. The method of claim 5 , wherein said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt has a melting point of about 167.5° C. by differential scanning calorimetry.

7. The method of claim 5 , wherein said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt is anhydrous.

8. The method of claim 1 , further comprising adding said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine monohydrate to acetone in water solution; and heating reaction mixture at a temperature of about 50° C. under suitable conditions, thereby providing a 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt.

9. The method of claim 8 , wherein said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt has a dehydration point at about 61° C. by differential scanning calorimetry.

10. A method for preparing 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt, comprising contacting 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid with meglumine under suitable conditions, thereby providing 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt.

11. The method of claim 10 , comprising adding 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid and meglumine to methanol thereby providing a suspension; and heating said suspension under suitable conditions.

12. The method of claim 11 , comprising heating said suspension at about 80° C.

13. The method of claim 10 , wherein said 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid meglumine salt has a melting point of about 180.6° C. by differential scanning calorimetry.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: CHIANELLI, DONATELLA; LIU, XIAODONG; MOLTENI, VALENTINA; NELSON, JOHN; ROLAND, JASON THOMAS; RUCKER, PAUL VINCENT; TULLY, DAVID C.
To: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
Reel/Frame 055262/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
To: IRM LLC
Reel/Frame 055262/0089 →
MERGER Recorded Feb 15, 2021
From: IRM LLC
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Reel/Frame 055262/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
Reel/Frame 055262/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
To: NOVARTIS AG
Reel/Frame 055262/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: ZHOU, BO
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 055262/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD
To: NOVARTIS AG
Reel/Frame 055262/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 055262/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: WAYKOLE, LILADHAR MURLIDHAR; ZHANG, YUBO; WANG, XIAOYANG; LI, RUNYAN
To: CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD
Reel/Frame 055304/0345 →
Continuity (5)
Division 16056881 · Aug 7, 2018
Continuation 15598734 · May 18, 2017
Continuation 15034280
Provisional Application 61900013 · Nov 5, 2013
Related Publication 20200247757A1 · Aug 6, 2020